Pharmanutra
Pharmanutra S.p.A., headquartered in Italy, is a leading player in the nutraceutical and pharmaceutical industry, specialising in the development of innovative dietary supplements and medical devices. Founded in 2003, the company has achieved significant milestones, including the introduction of its flagship product, SiderAL, which is renowned for its unique formulation of iron and its high bioavailability. With a strong presence in Europe and expanding operations in international markets, Pharmanutra is committed to enhancing health and well-being through scientifically-backed solutions. The company’s core offerings, including SiderAL and other mineral-based supplements, are distinguished by their patented technologies and rigorous clinical research. Recognised for its excellence, Pharmanutra continues to solidify its market position as a trusted provider of high-quality health products, contributing to advancements in nutritional science.
DitchCarbon Score
How does Pharmanutra's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Pharmanutra's score of 38 is higher than 72% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Pharmanutra's reported carbon emissions
In 2023, Pharmanutra reported total carbon emissions of approximately 1,000,000 kg CO2e, with emissions distributed across various scopes. Specifically, Scope 1 emissions were about 229,189 kg CO2e, while Scope 2 emissions totalled approximately 270,515 kg CO2e (market-based) and 186,460 kg CO2e (location-based). Additionally, Scope 3 emissions included significant contributions from business travel at around 684,328 kg CO2e and employee commute at approximately 86,782 kg CO2e. In the previous year, 2022, Pharmanutra's emissions were approximately 287,850 kg CO2e for Scope 1 and 88,699 kg CO2e for Scope 2, alongside Scope 3 emissions from purchased goods and services and waste generated in operations. The company has shown a trend of increasing emissions over the years, with 2021 emissions at about 203,985 kg CO2e for Scope 1 and 66,020 kg CO2e for Scope 2. Despite the lack of specific reduction targets or initiatives disclosed, Pharmanutra's commitment to transparency in reporting emissions across all three scopes indicates a recognition of their environmental impact. The company continues to monitor and disclose its carbon footprint, aligning with industry standards for sustainability and climate accountability.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 92,590 | 000,000 | 000,000 | 000,000 |
| Scope 2 | 61,095 | 00,000 | 00,000 | 000,000 |
| Scope 3 | - | - | 000,000.00 | 000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Pharmanutra is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
